3,4-Diaminopyridine

3,4-Diaminopyridine
	120px
Systematic (IUPAC) name
	3,4-Diaminopyridine
Clinical data
Routes of; administration	Oral
Legal status
Legal status	Phase III;
Pharmacokinetic data
Bioavailability	30% ,
Identifiers
CAS Number	54-96-6
PubChem	CID 5918
ChemSpider	5705
Chemical data
Formula	C5H7N3
Molar mass	109.13[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

3,4-Diaminopyridine is an organic compound with the formula C₅H₃N(NH₂)₂. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.

Applications

3,4-Diaminopyridine experimental drug for the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca²⁺ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca²⁺ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate. It is also used to treat many of the Congenital Myasthenic Syndromes.

This compound has also been proposed for the treatment of multiple sclerosis.^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This pharmacology-related article is a stub. You can help ssf by expanding it.

fa:۳و۴-دی آمینو پیریدین nl:3,4-diaminopyridine

↑ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve. 24 (9): 1236–1238. doi:10.1002/mus.1139. PMID 11494280.
↑ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome". Acta Neurol Scand. 88 (2): 136–140. doi:10.1111/j.1600-0404.1993.tb04205.x. PMID 8213058.
↑ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864.

[1] AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve. 24 (9): 1236–1238. doi:10.1002/mus.1139. PMID 11494280.

[2] Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome". Acta Neurol Scand. 88 (2): 136–140. doi:10.1111/j.1600-0404.1993.tb04205.x. PMID 8213058.

[3] Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864.

[1]

[2]

[3]

v t e Channel blocker: potassium channel blockers
Antiarrhythmic III/delayed rectifier	benzofuran (Amiodarone) • quaternary ammonium (Bretylium) • naphthalene (Bunaftine) • phenethylamine (Dofetilide) • sulfonamide (Ibutilide) • pyrimidinone (Nifekalant) • ethanolamine (Sotalol) • cyclopropane (Tedisamil) • E-4031
Other/ungrouped/unknown	aminopyridine (3,4-Diaminopyridine, 4-Aminopyridine) • indole (Linopirdine, Paxilline) • quaternary ammonium (Tetraethylammonium) • peptide (Maurotoxin, Charybdotoxin)

3,4-Diaminopyridine

Applications

See also

References

Navigation menu

Views

Personal tools

Navigation

Search

Tools

adverts